Close Menu

NEW YORK (GenomeWeb) – OncoCyte reported after the close of the market on Tuesday that its third quarter net loss more than doubled amid higher operating expenses.

The company also disclosed a delay in the planned commercial launch of its first product, the liquid biopsy lung cancer diagnostic DetermaVu, due to technical issues during a clinical validation study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.